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In addition to regulating the activation of nuclear factor (NF)-kB and c-Jun N-terminal kinase (JNK), TGF-b activated
kinase 1 (TAK1) also upregulates the activation of AMP-activated protein kinase (AMPK) and autophagy. In the liver,
TAK1-mediated autophagy plays a role in preventing excessive lipid accumulation induced by starvation and fat
overload. TAK1-mediated autophagy and inhibition of mechanistic target of rapamycin complex 1 (mTORC1) prevent
liver fibrosis and tumor development.
Main Text
TGF-b activated kinase 1 (TAK1), also
known as MAP3K7, is a serine/threonine
kinase that belongs to the MAP3K family.
In the signaling pathways of IL-1b, toll-
like receptors (TLRs), TNFa, and TGF-
b, TAK1 regulates the activation of
nuclear factor (NF)-kB and c-Jun N-ter-
minal kinase (JNK).1 To examine the
physiological role of TAK1 in the liver,
we generated hepatocyte-specific Tak1-
deficient (Tak1DHEP) mice. Surprisingly,
these mice develop spontaneous liver dam-
age that leads to chronic liver inflamma-
tion, fibrosis, and carcinogenesis.2 The
ablation of Tak1 in hepatocytes promotes
hepatocyte apoptosis and compensatory
hepatocyte proliferation due to failure to
activate the survival function of NF-kB.
This aberrant hepatocyte regeneration, in
combination with chronic liver inflamma-
tion, ultimately results in the development
of hepatocellular carcinoma in TAK1DHEP
mice. However, another group reported
that additional deletion of Ikbkg (also
known as Nemo), an essential modulator
of IkB kinase (IKK) and NF-kB activa-
tion, reduces the spontaneous liver dam-
age, inflammation, fibrosis, and cancer in
Tak1DHEP mice.3 This suggests that mech-
anisms regulated by TAK1 other than the
NF-kB pathway are responsible for the
regulation of the liver pathology that
develops in Tak1DHEP mice.
Several studies have reported that TAK1
also activates AMP-activated protein kinase
(AMPK) and autophagy.4 Our recent work
demonstrates the pathophysiological role of
TAK1-mediated autophagy in the liver.
Fasting is a physiological inducer of autoph-
agy in the liver. Fasted wild-type (WT) mice
show induction of hepatic autophagy
accompanied by decreased expression of
p62 (also known as sequestosome or
SQSTM11) and activity of mechanistic tar-
get of rapamycin complex 1 (mTORC1).
To our surprise, hepatic Tak1 deficiency
suppressed autophagy induction and res-
cued the decrease in p62 expression and
mTORC1 activity upon fasting.5 Nutrient
deprivation or sensing an increased AMP/
ATP ratio activates AMPK through liver
kinase B 1 (LKB1), which directly and indi-
rectly phosphorylates unc-51 like autophagy
activating kinase (ULK1) and subsequently
induces autophagy. We found that starva-
tion-induced phosphorylation of LKB1,
AMPK, and ULK1 and autophagy are
TAK1-dependent in hepatocytes. Using
microtubule-associated protein 1 light chain
3b (LC3B)-GFP transgenic mice, we found
that basal levels of conversion of LC3BI to
LC3BII protein, free GFP generation from
the LC3B-GFP fusion protein, and mRNA
levels of autophagy-related genes (e.g., Atg3,
Atg5, and Ulk1) are downregulated in
Tak1-deficient livers.5 This indicates that
TAK1 regulates not only autophagy induced
through AMPK activation, but also basal
autophagy through transcriptional control
of the expression of autophagy-related genes.
A recent report demonstrated that TAK1
also mediates autophagy through S6K1
independently of AMPK, which may be
another mechanism for the regulation of
basal autophagy through TAK1.6
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AUTHOR'S VIEW
AMPK and mTORC1 are suggested to
be downstream of TAK1. Indeed, overex-
pression of a constitutively active form of
AMPK and treatment with rapamycin, an
mTORC1 inhibitor, induces autophagy
in Tak1-deficient hepatocytes.5 Rapamy-
cin treatment of TAK1-deficient hepato-
cytes significantly induces autophagy, but
to a lower level than that in WT cells.
This suggests that the regulation of
autophagy by TAK1 is modulated not
only by AMPK and mTORC1, but also
by other pathways such as IKK signaling,
as reported previously.7 A physiological
function of TAK1-mediated autophagy is
to prevent excessive lipid accumulation
through lipophagy, a type of autophagy
that degrades intracellular lipid droplets.
Fasting increases hepatic uptake of circu-
lating fat released from peripheral fat tis-
sues, but hepatic fat accumulation is
tightly regulated by lipophagy to prevent
excessive fat accumulation. In contrast,
upon fasting the livers of Tak1DHEP mice
dramatically changed to a white color,
reflecting excessive accumulation of fat in
hepatocytes due to the lack of lipophagy.5
We observed autophagic vesicles attached
to lipid droplets in WT livers using elec-
tron microscopy, but autophagic vesicles
were rarely seen in Tak1DHEP livers.
Although IkbkbDHEP mice have
reduced autophagy induction,7 fasting
does not cause a fatty liver appearance in
these mice (Seki, unpublished observa-
tion). This suggests the existence of
another mechanism in addition to autoph-
agy that promotes hepatic lipid degrada-
tion. mTORC1 is known to negatively
regulate peroxisome proliferator-activated
receptor (PPAR) a-mediated functions.8
Given the pronounced upregulation of
mTORC1 activity, hepatic PPARa activ-
ity is suppressed in Tak1DHEP livers.
Expression of PPARa-inducible genes
(e.g., Acox1, Cpt1, and Hmgcs2) and
PPARa-mediated b-oxidation were
markedly suppressed by the loss of Tak1.5
Suppression of lipophagy and PPARa-
mediated b-oxidation promotes lipid
accumulation in the liver. Accordingly, a
high-fat diet (HFD) challenge augmented
hepatic steatosis and inflammation in
Tak1DHEP mice as a result of the strong
suppression of autophagy and b-oxidation
by Tak1-deficiency.5 Intriguingly, insulin
resistance is comparable between WT and
Tak1DHEP mice with high fat diet (HFD)
feeding, which suggests a dissociation
between hepatosteatosis/ steatohepatitis
and insulin resistance.
Alternatively, the role of TAK1-medi-
ated autophagy can be examined through
forced induction of autophagy by admin-
istration of rapamycin to Tak1DHEP mice.
In contrast to the severe fatty liver appear-
ance in fasted Tak1DHEP mice, rapamycin
treatment suppressed hepatic fat accumu-
lation in these mice.5 We confirmed that
the effect of rapamycin on the reduction
of fat accumulation is largely dependent
on autophagy using Atg5-silenced hepato-
cytes.5 We also found decreased hepatic
expression of TAK1 in advanced fatty liver
disease, suggesting a mechanism whereby
a decrease in TAK1 in advanced fatty liver
suppresses autophagy and increases
mTORC1 activity, which further aug-
ments hepatosteatosis and liver inflamma-
tion and fibrosis, ultimately causing
carcinogenesis Figure 1.
Since our previous study showing that
autophagy defects are associated with liver
tumor development,9 we have examined
the role of autophagy defects in the devel-
opment of liver fibrosis and tumorigenesis
in our mouse model. Rapamycin-induced
autophagy significantly suppressed sponta-
neous hepatocyte injury, liver fibrosis, and
tumorigenesis in Tak1DHEP mice.5 This
suggests that TAK1-mediated autophagy
plays a role in preventing spontaneous
liver fibrosis and cancer. The clinical rele-
vance of TAK1 in human non-alcoholic
steatohepatitis (NASH) and hepatocarci-
nogenesis is currently unknown, but once
its clinical relevance in human liver disease
is understood, targeting TAK1 or TAK-1–
mediated autophagy could be an impor-
tant option for the prevention and treat-
ment of human liver disease.
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Figure 1. TAK1-mediated autophagy prevents hepatic steatosis and tumorigenesis. Upon nutrition
deprivation, TGF-b activated kinase 1 (TAK1) mediates autophagy through activation of AMP-acti-
vated protein kinase (AMPK) and inhibition of mechanistic target of rapamycin complex 1
(mTORC1). TAK1 is also associated with induction of peroxisome proliferator-activated receptor
(PPAR) a-mediated fatty acid oxidation (FAO) through suppression of mTORC1. Both autophagy
and FAO contribute to lipid breakdown to prevent excessive lipid accumulation in hepatocytes.
Autophagy prevents, and mTORC1 enhances, spontaneous tumorigenesis in the liver.
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